Compare Atlassian Corporation PLC (TEAM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs Twist Bioscience Corp — how do they compare? Atlassian Corporation PLC trades at $176.91 (market cap $44.99B), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Atlassian Corporation PLC is far larger — about 5.4× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| TEAM | TWST | |
|---|---|---|
Market Cap | $44.99B | $8.26B |
Sector | Technology | Health |
52-Week High | $194.68 | $153.10 |
52-Week Low | $57.15 | $24.16 |
Enterprise Value | $44.99B | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $176.42, down 6.94% over 24 hours but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and a neutral RSI. Fundamentally, revenue growth is robust, climbing to $5.22B in 2025, though net income margins are negative. Recent earnings beats and AI integration into products like Rovo highlight operational strength, but high valuations and insider sales warrant caution.
Outlook is cautiously optimistic; analyst consensus is bullish with a $179.81 price target, driven by AI adoption and cloud expansion. Risks include premium valuation metrics, persistent net losses, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
